Voyage Through Time

In the 1960s, because of its professional and efficient organization, Schazoo entered into licensing

agreements with International Companies of repute like:










UPJOHN (Merged with Pfizer)



LEPETIT (Merged with Aventis)












In 1986, Schazoo Laboratories achieved the International Asia Award for Quality.

In 2002, Schazoo became an ISO 14001 certified organization

In July 2008, Schazoo Zaka (Pvt) Ltd shifted to a new purpose built state-of-the-art production facility

In 2012, Schazoo Zaka obtained the Laboratory Management System ISO 17025 Accreditation from PNAC (Pakistan National Accreditation Council)

In 1999, Schazoo earned ISO 9001 certification of Quality.

In 2004, The Schazoo Laboratories (Pvt) Ltd. was expanded into two companies i.e. Schazoo Zaka (Pvt) Ltd.

In 2009, ISO 9001:2008 Quality Management System Certification and ISO 14001:2004 Environmental Management System certification were awarded.


Today, Schazoo Zaka is one of the fastest growing national pharmaceutical company in Pakistan. The Company’s name is associated with reliability, honor and quality. It has been tested and approved over time by other Associated Companies, Doctors and Customers.

With a wide range of products covering the major therapeutic classes, having a purpose built manufacturing unit, cGMP practices, and major focus of Quality Assurance & Control, Schazoo Zaka continues to follow its vision of leading the way to a healthier world.

Schazoo Zaka is working in the following segments/therapeutic classes:

  1. Anti-Tuberculosis
  2. Respiratory Diseases Drugs
  3. Cardiovascular Drugs
  4. Bone & Muscle Health
  5. Pain Management
  6. Antibiotics
  7. Anti-Diabetics
  8. Anti-Obesity
  9. Anti-Malarial
  10. Gastrointestinal Products
  11. Nutraceuticals
  12. Anti Histamine


Schazoo Zaka will continue with its commitment of providing high quality healthcare products at affordable prices to the people of Pakistan, and also in the international market. The company remains committed to its vision of leading the way to a healthier world. Schazoo Zaka will continue to come up with more healthcare products according to international standards. We have several products to be launched down the road.

The company is moving into the international market aggressively and it has planned a strategy to leverage the global generics market. Our aim is to reach all the high burden tuberculosis countries and work with them as a partner to eradicate tuberculosis from their respective soil. The primary goal of WHO’s Global Drug Facility (GDF) is to ensure reliable access to affordable TB drugs of known quality for DOTS program. As we are already supplying Anti-TB products to DOTS program in Pakistan, we intend to broaden this horizon to other markets through GDF procurement program.

As sales force is the most effective tool for the promotion of products, hence the following capabilities will be targeted in the sales staff for a better future:

  • Recruiting and retaining the best talent with better remunerations.
  • Train them with the relevant selling skills and product knowledge.

The strategy towards the markets of the future not only comprises of creating capacities and physical assets; it incorporates a strong movement by Schazoo Zaka towards entering into strategic alliances and enhancing resident intellectual capital and adding value. Schazoo Zaka will continue to provide a professional working environment. The company will remain an equal opportunity employer. The Management is dedicated to make further investments in improving company operations.

The company has already entered the Nutraceuticals/Herbal formulations segment and plans to launch more products in this area. In addition, Schazoo Zaka is also manufacturing formulations for Pediatric tuberculosis having a pharmacologically recommended therapy for the treatment of tuberculosis in children. These formulations will take care of the little patients suffering from tuberculosis in high burden countries.

Besides Anti-TB drugs, Schazoo Zaka has a wide variety of products including Cardiovascular, Antidiabetic , products for orthopedic and respiratory diseases. In line with the company objectives, we will acquire significant share of these therapeutic classes from the target market.